Monday, 8 November 2010

Pelvic Floor Biofeedback Therapy/Retraining

A little post giving some information relating to Pelvic Floor Biofeedback Therapy/Retraining:

The Mediwatch solutions



(Venus-US only at present time)



And the associated pdf:



What's it all about....


Introduction

Pelvic floor biofeedback therapy is a treatment intended to help patients learn to strengthen and relax their pelvic muscles in order to improve bladder function and decrease pelvic pain. Biofeedback uses electronic and mechanical instruments to accurately measure the action of the pelvic floor muscles, and provides ‘feedback’ information to the patient so that the patient can learn to better use the pelvic muscles. Patients can learn to use the pelvic floor muscles to decrease the sudden urge to urinate, decrease incontinence, and lessen certain types of pelvic pain. An important part of pelvic floor biofeedback therapy is consistent exercise of the pelvic muscles at home, and biofeedback therapy can help teach proper pelvic muscle exercise.

Pelvic floor biofeedback therapy has been used successfuly by many men and women for the past thirty years, and the 1992 & 1996 AHCPR (Agency for Health Care Policy and Research) Guideline on Urinary Incontinence listed biofeedback as a useful treatment option for reducing the symptoms of incontinence. More recently pelvic floor biofeedback therapy, along with pelvic floor muscle massage and "trigger point release" therapy, have been found to be helpful in men and women with chronic pelvic pain. Monterey Bay Urology Associates employ a pelvic therapy clinician, Kathy Cliff, who specializes in pelvic floor therapy in men and women. We have had excellent results with this type of treatment in patients with bothersome urinary incontinence and pelvic pain.(More)

Sunday, 7 November 2010

Movember Updates

Prostate Cancer increase life expectancy?

Interesting article relating to German researchers and highlighted on 'The "New" Prostate Cancer InfoLink' website:

Could having a diagnosis of localized prostate cancer increase life expectancy?

Posted on November 5, 2010

In what can only be described as an unexpected finding, a group of German researchers have documented a greater life expectancy for men diagnosed with early stage prostate cancer than for the male population in general, based on data from the Regensburg cancer registry!
Klotz et al. used epidemiological data from the Regensburg cancer registry to study the survival of patients diagnosed with organ-confined prostate cancer (T1-2N0M0) compared to the standardized age-adjusted survival of the normal male population.

Their analysis is based on data from 4,124 patients with prostate cancer diagnosed between 1998 and 2007, of whom 2,087 men had been diagnosed with localized disease. Here is what they claim to have been able to find:

•At 8 years after diagnosis, patients with T1-2N0Mo prostate cancer had a roughly 10 percent relative increase in survival compared with the normal male population.
•This relative increase in survival could be documented just 3 years after diagnosis.
What could possibly account for such a finding?

It can’t be explained by prostate cancer treatment, because any survival benefit from treatment takes at least 8 to 10 years and maybe longer (based on data from the ERSPC trial). The immediate implication is that (at least in Regensburg) men who have PSA tests (and therefore greater likelihood for a diagnosis of prostate cancer) may have better overall health status than men who do not.

This is not an entirely unreasonable suggestion. There is a well-understood phenomenon that associates positive health-related (“health-seeking”) behaviors with all sorts of other factors. Elsewhere on this site, we discuss the fact that although men who have vasectomies seem to be at greater risk for prostate cancer than men who do not have vasectomies, this is not because they have the vasectomies. Rather, it is because they exhibit such “health-seeking” behavior.

We suspect that in Regensburg (and potentially in many other places) having a PSA test is closely correlated with having regular health checks. Men who have regular health checks arguably may have a superior life expectancy to those who see doctor only when they absolutely have to (although such a benefit has never actually been documented, as far as we know). The other issue that then comes into play is whether men of higher income and/or better education are more likely to have regular health checks than those less fortunate. The authors refer to this in their paper as the relationship between PSA testing and a “socal gradient.”

Could having a diagnosis of localized prostate cancer increase life expectancy?

Monday, 1 November 2010

It's Movember!



Mediwatch-OEM Partnership with ACON Laboratories

1 November 2010

Mediwatch plc

OEM Partnership with ACON Laboratories

Mediwatch Plc ("Mediwatch" or "the Company", AIM: MDW), the innovative urological diagnostic manufacturing company, has entered into an Original Equipment Manufacture ("OEM") partnership with ACON Laboratories Inc. ("ACON") to distribute urinalysis products.

This partnership includes a distribution agreement that was signed by Mediwatch to distribute worldwide the ACON line of urinalysis products under the Mediwatch brand, Urinewatch. The worldwide urinalysis market is estimated to be worth over $500 million in annual sales.

ACON is an internationally renowned diagnostic company with manufacturing and distribution in China and the US. This company has been a leader in the production of quality diagnostic tests in their particular field.

Mediwatch is excited to have the opportunity of working with this international group and to add this new diagnostic product to its exclusive urology diagnostic range.

Philip Stimpson, Mediwatch's Chief Executive commented:

"This is an excellent opportunity for Mediwatch to expand its one-stop shop offering for Urologists."

OEM Partnership with ACON Laboratories



FUTURE EVENTS AND LATEST NEWS(Updated 2nd Nov)





Latest News/Website Updates

Director's Shareholding 2nd November

OEM Partnership with ACON Laboratories 1st November



Mediwatch Positions/Jobs



Mediwatch Training Courses

Mediwatch USA- Basic Urodynamics Clinicians’ Workshop 13th-14th November 2010



Future Events

Events where Mediwatch are attending/exhibiting will be marked as so or updated,hopefully before the event is finished.More Events to add later

British Association of Urological Nurses Annual Conference and Exhibition UK 4th-5th November 2010 Mediwatch are Exhibiting

28th Biennial Congress of the Urological Association of South African South Africa 16th-19th November 2010 Mediwatch distributor 'Tecmed Africa'are Exhibiting

19th Malaysian Urological Conference Malaysia-25th-28th November 2010


STUFF THAT MAYBE DID BUT NOW
DOESN'T FIT IN WITH THE TITLE...


Website Update (Aug)-Mobile Watch

Interim Results

Mediwatch Newsletter-July 2010 Edition

OEM Partnership with Thought Technology Ltd Mediwatch-14th June

Distribution Agreement with GE Healthcare Mediwatch-8th June

Director Shareholding 4th May

Director Shareholding 14th April


Mediwatch Annual Report 2009


December/January Mediwatch Newsletter

Mediwatch Interim Results for the six month ended 30 April 2009

Five year global distribution agreement secured with Inverness Medical Innovations-16 March 2009

Preliminary Results for the year ended 31 October 2008-Issued 26 January 2009